Study Supports Use of Insulin Lispro in PumpsIn the May 5, 1999 issue of Diabetes Care, researchers from Germany published the results of a study that examined the efficacy and tolerability of Insulin Lispro [Humalog] in pumps. 113 patients with Type 1 diabetes who used an insulin pump participated in the open, randomized crossover study. Each used Regular or Insulin Lispro for four months. The study looked at HbA1c, daily and postprandial blood glucose profiles, adverse events, rate of hypoglycemic and hyperglycemic events, catheter obstructions, and patient statisfaction.
During the study, HbA1c levels decreased for all participants, but is was better during treatment with Insulin Lispro (Insulin Lispro: 6.8 +/- 0.9%, Regular: 6.9 +/- 1.0%). The one- and two-hour postprandial blood glucose rise was significantly lower when using Insulin Lispro. There were no significant differences in rates of hypoglycemia, catheter obstructions, or adverse events. Patients reported greater satisfaction when using Insulin Lispro.
Insulin Lispro is fast replacing Regular as the insulin of choice for users of pumps. [See our poll on insulin regimen.] This study supports the use of Insulin Lispro as a safe alternative to Regular.
[Diabetes Care 22:784-788, 1999]
Posted 16 May 1999
Last Updated: Thursday February 27, 2014 19:28:21
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents.
© Children with Diabetes, Inc. 1995-2016. Comments and Feedback.